Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024)

It could be beneficial for patients if agencies applied more scrutiny in the selection of which cancer drugs to grant priority review. Such drugs should have a high therapeutic value, and their review should be completed in a timely manner to enable quicker access to important cancer drugs for patients. Although the FDA would need to take the most substantial steps, EMA and Swissmedic could also improve their systems.